Evaluate molecularly targeted agents and immunotherapies approved or currently in clinical development for cancer treatment and incorporate into practice
Assess relevant, state-of-the-art or translational pre-clinical models of anti-cancer therapies
Recognize the steps and determinants of the metastatic process of cancer
Identify the barrier for immunotherapy and potential approaches to address them
Compare correlative studies of biomarkers and their response and resistance to targeted therapies in cancer patients
Evaluate state-of-the-art genetic and imaging techniques and their applications in pre-clinical and clinical studies
This is an accredited, livestreamed course offered by Masssachusetts General Hospital. This course is targeted to physicians and researchers.
Select the Take Course button to view additional information on the course registration page.
Contact ceprograms@hms.harvard.edu with questions.
